# Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

> **NCT01705106** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 21 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** capecitabine
- **DRUG:** celecoxib
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies

## Key facts

- **NCT ID:** NCT01705106
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08-29
- **Primary completion:** 2016-02-10
- **Final completion:** 2016-02-10
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** The study was terminated early due to slow accrual.
- **Last updated:** 2018-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01705106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01705106, "Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01705106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*